Related Experiment Video

Updated: May 12, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Antiangiogenic and antiapoptotic treatment in advanced melanoma

Vasiliki Nikolaou1, Alexander Stratigos, Dimitrios Bafaloukos

  • 1Department of Dermatology, University of Athens Medical School, A. Sygros Hospital, Athens, Greece.

Clinics in Dermatology
|April 24, 2013
PubMed

Insights

Targeted therapies show limited success alone for advanced melanoma. Combination treatments with chemotherapy are under investigation to improve survival rates for this aggressive skin cancer.

Area of Science:

  • Oncology
  • Dermatology
  • Molecular Biology

Background:

  • Melanoma is an aggressive skin cancer with poor survival rates for advanced stages.
  • Current treatments offer limited impact on patient survival.
  • Understanding molecular pathways has led to targeted therapy development.

Purpose of the Study:

  • To review the role of targeted therapies in advanced melanoma treatment.
  • To evaluate the efficacy of novel agents targeting angiogenesis and antiapoptotic proteins.
  • To assess the potential of combination therapies in melanoma management.

Main Methods:

  • Review of newly introduced targeted agents.
  • Investigation of agents targeting angiogenesis and antiapoptotic proteins.
  • Analysis of monotherapy versus combination therapy outcomes.

Main Results:

  • Monotherapy with targeted agents has shown disappointing results in melanoma.
  • The impact of combination therapy with cytotoxic chemotherapy is under investigation.
  • Larger phase III trials are required to determine clinical benefit.

Conclusions:

  • Targeted therapies alone have not significantly improved survival in advanced melanoma.
  • Combination strategies involving targeted agents and chemotherapy warrant further investigation.
  • Definitive evidence from phase III trials is needed to establish optimal treatment protocols.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...